Cerebrospinal fluid inflammatory biomarkers for disease progression in Alzheimer’s disease and multiple sclerosis: a systematic review
Inflammatory processes are involved in the pathophysiology of both Alzheimer’s disease (AD) and multiple sclerosis (MS) but their exact contribution to disease progression remains to be deciphered. Biomarkers are needed to define pathophysiological processes of these disorders, who may increasingly...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1162340/full |
| _version_ | 1797780813629095936 |
|---|---|
| author | Joke Temmerman Joke Temmerman Joke Temmerman Sebastiaan Engelborghs Sebastiaan Engelborghs Sebastiaan Engelborghs Maria Bjerke Maria Bjerke Maria Bjerke Maria Bjerke Miguel D’haeseleer Miguel D’haeseleer Miguel D’haeseleer |
| author_facet | Joke Temmerman Joke Temmerman Joke Temmerman Sebastiaan Engelborghs Sebastiaan Engelborghs Sebastiaan Engelborghs Maria Bjerke Maria Bjerke Maria Bjerke Maria Bjerke Miguel D’haeseleer Miguel D’haeseleer Miguel D’haeseleer |
| author_sort | Joke Temmerman |
| collection | DOAJ |
| description | Inflammatory processes are involved in the pathophysiology of both Alzheimer’s disease (AD) and multiple sclerosis (MS) but their exact contribution to disease progression remains to be deciphered. Biomarkers are needed to define pathophysiological processes of these disorders, who may increasingly co-exist in the elderly generations of the future, due to the rising prevalence in both and ameliorated treatment options with improved life expectancy in MS. The purpose of this review was to provide a systematic overview of inflammatory biomarkers, as measured in the cerebrospinal fluid (CSF), that are associated with clinical disease progression. International peer-reviewed literature was screened using the PubMed and Web of Science databases. Disease progression had to be measured using clinically validated tests representing baseline functional and/or cognitive status, the evolution of such clinical scores over time and/or the transitioning from one disease stage to a more severe stage. The quality of included studies was systematically evaluated using a set of questions for clinical, neurochemical and statistical characteristics of the study. A total of 84 papers were included (twenty-five for AD and 59 for MS). Elevated CSF levels of chitinase-3-like protein 1 (YKL-40) were associated with disease progression in both AD and MS. Osteopontin and monocyte chemoattractant protein-1 were more specifically related to disease progression in AD, whereas the same was true for interleukin-1 beta, tumor necrosis factor alpha, C-X-C motif ligand 13, glial fibrillary acidic protein and IgG oligoclonal bands in MS. We observed a broad heterogeneity of studies with varying cohort characterization, non-disclosure of quality measures for neurochemical analyses and a lack of adequate longitudinal designs. Most of the retrieved biomarkers are related to innate immune system activity, which seems to be an important mediator of clinical disease progression in AD and MS. Overall study quality was limited and we have framed some recommendations for future biomarker research in this field.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42021264741. |
| first_indexed | 2024-03-12T23:49:10Z |
| format | Article |
| id | doaj.art-3c4bc93f43234674933c31244eaaa5ee |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-12T23:49:10Z |
| publishDate | 2023-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-3c4bc93f43234674933c31244eaaa5ee2023-07-13T19:37:50ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-07-011410.3389/fimmu.2023.11623401162340Cerebrospinal fluid inflammatory biomarkers for disease progression in Alzheimer’s disease and multiple sclerosis: a systematic reviewJoke Temmerman0Joke Temmerman1Joke Temmerman2Sebastiaan Engelborghs3Sebastiaan Engelborghs4Sebastiaan Engelborghs5Maria Bjerke6Maria Bjerke7Maria Bjerke8Maria Bjerke9Miguel D’haeseleer10Miguel D’haeseleer11Miguel D’haeseleer12Vrije Universiteit Brussel, Center for Neurosciences (C4N), Jette, Brussels, BelgiumUniversiteit Antwerpen, Department of Biomedical Sciences and Institute Born-Bunge, Reference Center for Biological Markers of Dementia (BIODEM), Wilrijk, Antwerp, BelgiumUniversitair Ziekenhuis Brussel, Department of Neurology, Jette, Brussels, BelgiumVrije Universiteit Brussel, Center for Neurosciences (C4N), Jette, Brussels, BelgiumUniversiteit Antwerpen, Department of Biomedical Sciences and Institute Born-Bunge, Reference Center for Biological Markers of Dementia (BIODEM), Wilrijk, Antwerp, BelgiumUniversitair Ziekenhuis Brussel, Department of Neurology, Jette, Brussels, BelgiumVrije Universiteit Brussel, Center for Neurosciences (C4N), Jette, Brussels, BelgiumUniversiteit Antwerpen, Department of Biomedical Sciences and Institute Born-Bunge, Reference Center for Biological Markers of Dementia (BIODEM), Wilrijk, Antwerp, BelgiumUniversitair Ziekenhuis Brussel, Department of Neurology, Jette, Brussels, BelgiumUniversitair Ziekenhuis Brussel, Department of Clinical Biology, Laboratory of Clinical Neurochemistry, Jette, Brussels, BelgiumVrije Universiteit Brussel, Center for Neurosciences (C4N), Jette, Brussels, BelgiumUniversitair Ziekenhuis Brussel, Department of Neurology, Jette, Brussels, BelgiumNational MS Center (NMSC), Neurology, Melsbroek, Steenokkerzeel, BelgiumInflammatory processes are involved in the pathophysiology of both Alzheimer’s disease (AD) and multiple sclerosis (MS) but their exact contribution to disease progression remains to be deciphered. Biomarkers are needed to define pathophysiological processes of these disorders, who may increasingly co-exist in the elderly generations of the future, due to the rising prevalence in both and ameliorated treatment options with improved life expectancy in MS. The purpose of this review was to provide a systematic overview of inflammatory biomarkers, as measured in the cerebrospinal fluid (CSF), that are associated with clinical disease progression. International peer-reviewed literature was screened using the PubMed and Web of Science databases. Disease progression had to be measured using clinically validated tests representing baseline functional and/or cognitive status, the evolution of such clinical scores over time and/or the transitioning from one disease stage to a more severe stage. The quality of included studies was systematically evaluated using a set of questions for clinical, neurochemical and statistical characteristics of the study. A total of 84 papers were included (twenty-five for AD and 59 for MS). Elevated CSF levels of chitinase-3-like protein 1 (YKL-40) were associated with disease progression in both AD and MS. Osteopontin and monocyte chemoattractant protein-1 were more specifically related to disease progression in AD, whereas the same was true for interleukin-1 beta, tumor necrosis factor alpha, C-X-C motif ligand 13, glial fibrillary acidic protein and IgG oligoclonal bands in MS. We observed a broad heterogeneity of studies with varying cohort characterization, non-disclosure of quality measures for neurochemical analyses and a lack of adequate longitudinal designs. Most of the retrieved biomarkers are related to innate immune system activity, which seems to be an important mediator of clinical disease progression in AD and MS. Overall study quality was limited and we have framed some recommendations for future biomarker research in this field.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42021264741.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1162340/fullinflammationbiomarkersAlzheimer’s disease (AD)multiple scleorsis (MS)disease progression |
| spellingShingle | Joke Temmerman Joke Temmerman Joke Temmerman Sebastiaan Engelborghs Sebastiaan Engelborghs Sebastiaan Engelborghs Maria Bjerke Maria Bjerke Maria Bjerke Maria Bjerke Miguel D’haeseleer Miguel D’haeseleer Miguel D’haeseleer Cerebrospinal fluid inflammatory biomarkers for disease progression in Alzheimer’s disease and multiple sclerosis: a systematic review Frontiers in Immunology inflammation biomarkers Alzheimer’s disease (AD) multiple scleorsis (MS) disease progression |
| title | Cerebrospinal fluid inflammatory biomarkers for disease progression in Alzheimer’s disease and multiple sclerosis: a systematic review |
| title_full | Cerebrospinal fluid inflammatory biomarkers for disease progression in Alzheimer’s disease and multiple sclerosis: a systematic review |
| title_fullStr | Cerebrospinal fluid inflammatory biomarkers for disease progression in Alzheimer’s disease and multiple sclerosis: a systematic review |
| title_full_unstemmed | Cerebrospinal fluid inflammatory biomarkers for disease progression in Alzheimer’s disease and multiple sclerosis: a systematic review |
| title_short | Cerebrospinal fluid inflammatory biomarkers for disease progression in Alzheimer’s disease and multiple sclerosis: a systematic review |
| title_sort | cerebrospinal fluid inflammatory biomarkers for disease progression in alzheimer s disease and multiple sclerosis a systematic review |
| topic | inflammation biomarkers Alzheimer’s disease (AD) multiple scleorsis (MS) disease progression |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1162340/full |
| work_keys_str_mv | AT joketemmerman cerebrospinalfluidinflammatorybiomarkersfordiseaseprogressioninalzheimersdiseaseandmultiplesclerosisasystematicreview AT joketemmerman cerebrospinalfluidinflammatorybiomarkersfordiseaseprogressioninalzheimersdiseaseandmultiplesclerosisasystematicreview AT joketemmerman cerebrospinalfluidinflammatorybiomarkersfordiseaseprogressioninalzheimersdiseaseandmultiplesclerosisasystematicreview AT sebastiaanengelborghs cerebrospinalfluidinflammatorybiomarkersfordiseaseprogressioninalzheimersdiseaseandmultiplesclerosisasystematicreview AT sebastiaanengelborghs cerebrospinalfluidinflammatorybiomarkersfordiseaseprogressioninalzheimersdiseaseandmultiplesclerosisasystematicreview AT sebastiaanengelborghs cerebrospinalfluidinflammatorybiomarkersfordiseaseprogressioninalzheimersdiseaseandmultiplesclerosisasystematicreview AT mariabjerke cerebrospinalfluidinflammatorybiomarkersfordiseaseprogressioninalzheimersdiseaseandmultiplesclerosisasystematicreview AT mariabjerke cerebrospinalfluidinflammatorybiomarkersfordiseaseprogressioninalzheimersdiseaseandmultiplesclerosisasystematicreview AT mariabjerke cerebrospinalfluidinflammatorybiomarkersfordiseaseprogressioninalzheimersdiseaseandmultiplesclerosisasystematicreview AT mariabjerke cerebrospinalfluidinflammatorybiomarkersfordiseaseprogressioninalzheimersdiseaseandmultiplesclerosisasystematicreview AT migueldhaeseleer cerebrospinalfluidinflammatorybiomarkersfordiseaseprogressioninalzheimersdiseaseandmultiplesclerosisasystematicreview AT migueldhaeseleer cerebrospinalfluidinflammatorybiomarkersfordiseaseprogressioninalzheimersdiseaseandmultiplesclerosisasystematicreview AT migueldhaeseleer cerebrospinalfluidinflammatorybiomarkersfordiseaseprogressioninalzheimersdiseaseandmultiplesclerosisasystematicreview |